Final Program [International Conference on AIDS (14th: 2002: Barcelona, Spain)]

Wednesday lulv 1o

Poster Exhibitions.

WePeB6oo3 Traditional medicine, HAART and HIV infection:
a prevalence study in French Guiana
P Couppid, FBissuel, M Sobesky, R Renau-Ferrer,
G Flexor, D Vernon, A Ehrlacher, M El Guedj,
R Pradinaud (French Guiana)
WePeB600oo4 Trends in complementary/alternative medicine
(CAM) use in a large cohort of HIV infected
women in the US from 1994-2001
K Weber, M Schneider, H Sacks, M Young,
R Greenblatt, T Wilson, B Heikes, S Kim
(United States)
WePeB6oo5 HAART related side effect and use of
Complementary Therapy (CT) among HIV+ people
P Nasta', F Chiaffarino', V Agnoletto', FParazzini',
C Mann2, K Kokkas3, N Culler4
(Italy; 2United Kingdom; 3Greece; 4Spain)
WePeB6oo6 Could the use of complementary therapies
influence the adherence to HAART regimen?
P Nasta', VAgnoletto', F Chiaffarino', F Parazzini',
C Sala', G Weiler2, K Kokkas3
('Italy; 2Germany; 3Greece)
WePeB6oo7 Complementary medicine use among HIV+
persons: level of information and perception of
HAART- herbs interactions risks
P Nasta', V Agnoletto', F Chiaffarino', F Parazzini',
C Mann2, N Culler3, Y Behar4, K Kokkass5
('Italy; 2United Kingdom; 3Spain; 4France;
5Greece)
WePeB6oo8 Use of marijuana among people with HIV and its
relationship to adherence to antiretroviral
treatment, use of alternative therapies and
complete viral suppression in a public health care
setting in northern California
D E Prentiss, M G Balmas, R Power, D M Israelski
(United States)
WePeB6oo9 The effect of wild garlic extracts on AIDS related
fungal and bacterial pathogens
Q Johnson, F Weitz, W Mabusela, J Klaasen
(South Africa)
WePeB6oio The use of Chinese herbal medicine by HIVinfected patients in China, Taiwan and Hong Kong
VSo (Venezuela)
WePeB6o11 Safety and efficacy of New-Fill (Polylactic acid) in
the treatment of HIV-Associated Lipoatrophy of
the face (HALF)
P Engelhard, M Knies (United States)
WePeB6o12 Durability of antiretroviral benefit in a university
hospital in Brazil
R Medeiros R S Diaz, A Castelo (Brazil)
WePeB6o13 Trends in the use of antiretrovirals in the south of
Spain, 1996-2ooo000
F Lozano, M A Colmenero, M Mdrquez,
F Guerrero, J Hernfdndez-Quero, J Pasquau,
A Terrdn, /] Herndndez-Burruezo, V GutidrrezRav, M Delgado, A Arco, B Valera (Spain)
WePeB6o14 HIV and HBV coinfection in patients attending
some hospitals in Douala and Yaounde Cameroon
C P L Nqansop Kenmogne Kaptue (Cameroon)
WePeB6o15 Anti-Hepatitis B Virus (HBV) activity of Tenofovir
Disoproxil Fumarate (TDF) in Lamivudine (LAM)
experienced HIV/HBV co-infected patients
D Cooper', A Cheng2, D F Coakley2, Sayre2,
L Zhong2, SS Chen2, C Westland, M D Miller,
C Brosgart ('Australia; 2United States)
WePeB6oi6 The role of hepatitis B virus in the progression of
HIV and the response to highly active
antiretroviral therapy (HAART)

CL Thio, E C Seaberg, L Kingsley, J Phair,
B Visscher, A Mufioz (United States)

WePeB6o17 Influence of past hepatitis B infection upon risk
of highly active antiretroviral therapy induced
hepatoxicity
M Hoffman-Terry, A Smith, E O'Donnell, T Wasser
(United States)
WePeB6oi8 Efficacy and safety of therapy with interferon and
ribavirin in HIV infected patients with chronic
hepatitis C
F Sanchez Montero (Spain)
WePeB6o19 Study of the attitude and practice of hemodialysis
Nurses in preventing of Hepatitis type (C) and (B)
A Marbaqhi S Saheli, A Najaf Yarandi, E Ebrahimi
(Islamic Republic of Iran)
WePeB6o2o Risk for the Development of HCV-related fibrosis
in H IV Positive Patients
K A Stellrecht, B McKenna, E Graffunder
(United States)
WePeB6o21 Seroprevalence of HBV, HCV and HIV among
blood donors in and around Calcutta (Kolkata),
State West Bengal, India
SK D Dey, N K P Pal, P KSSenBarat,
SK D De (India)
WePeB6o22 Evaluation and treatment of HIV+ veterans
coinfected with hepatitis C
SL Fultz, A Butt, S Weissman, L Rabeneck,
A C Justice (United States)
WePeB6o23 Liver biopsy in HIV/HCV-Coinfected patients
G Klausen I Kolberg, F Niedobitek, J Goelz,
A Moll, D Schleehauf, D Prziwara, C Cordes
(Germany)
WePeB6024 The role of hepatitis infection and nevirapine on
liver abnormalities among HIV patients
VM Nasiff M Beltran, R Gil, N Sanga (Argentina)
WePeB6025 Pegylated Interferon-alpha and Ribavirin Therapy
for Hepatitis C in HIV-coinfected patients: 24
weeks results
JK Rockstroh C Schulz, S Mauss, G Klausen,
E Voigt, J Gdlz (Germany)
WePeB6026 Hepatitis C virus infection among patients
attending sexually transmitted disease clinics
with and without HIV-1 Infection in Pune, India
A R Risbud', M Pareira', SM Mehendale',
R R Gangakhedkar', S NJoshi', S P Tripathy',
R C Bollinger2, R S Paranjape' (lndia; 2United States)
WePeB6o27 Necessity of prevention for vertical transmission
of hepatitis C virus among co-infected both HIV
and HCV women
SY Zverev, 0 V Novikova, EA Zemskova
(Russian Federation)
WePeB6o28 Efficacy and tolerability of HCV treatment in HIVHCV co-infected patients: the potential role of
HCV genotype
I Poizot-Martin, C Marimoutou, S Benhaim,
M P Drogoul-Vey, F Vion-Dury, C Tamalet,
IA Gastaut (France)
WePeB6o29 No difference in virological and immunological
response to HAART according to HCV genotype
and viral load in a cohort of HIV/HCV co-infected
patients
G Antonucci, A Cozzi-Lepri2, M Solmone',
A De Luca', C Pastecchia', G Madeddu', P Piano',
A Vincenti, F Carletti' ('Italy; 2United Kingdom)
WePeB6o3o Insulin resistance (IR) and prevalence of diabetes
mellitus (DM) in antiretroviral (ARV) naive
patients coinfected with hepatitis C (HCV) and
HIV-1 compared to patients with HIV-i infection
alone For The Terry Beirn Community Programs

for Clinical Research on AIDS
F Visnegarwala, L Chen, S Raghavan, E Tedaldi
(United States)
XIV International AIDS Conference BARCELONA - JULY 7-12

Wednesday

165